person · Reporting owner

Bickerstaff George

Disclosed activity across 5 companies

Tapewire entity: 25799
SEC CIK: 0001329646

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CareDx, Inc.CDNA · Entity 4344	Director	August 05, 2026	August 06, 2026
INOVIO PHARMACEUTICALS, INC.INO · Entity 6589	Director	March 21, 2018	March 22, 2018
Innoviva, Inc.INVA · Entity 4679	Director	April 25, 2022	April 27, 2022
Sio Gene Therapies Inc.AXGT · Entity 130622	Director	April 15, 2019	April 18, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CareDx, Inc.

Report date August 05, 2026 · Filed August 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	134,061	Reported balance After 2026-08-05 transaction · row 1 1 source row Row 1 · 2026-08-05 · Sale · Disposed 20,000 · Balance 134,061 F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.14 to $47.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.14 to $47.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

INOVIO PHARMACEUTICALS, INC.

Report date March 21, 2018 · Filed March 22, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,090	Reported balance After 2018-03-21 transaction · row 1 1 source row Row 1 · 2018-03-21 · Exercise / conversion · Acquired 4,090 · Balance 4,090 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	8,180	Reported balance After 2018-03-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-21 · Exercise / conversion · Disposed 4,090 · Balance 8,180 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares vested on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.

Innoviva, Inc.

Report date April 25, 2022 · Filed April 27, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	137,207	Reported balance After 2022-04-25 transaction · row 1 1 source row Row 1 · 2022-04-25 · Grant · Acquired 12,647 · Balance 137,207 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.
Non-statutory Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.79 · Expires 2032-04-24	Direct	10,000	Reported balance After 2022-04-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-04-25 · Grant · Acquired 10,000 · Balance 10,000 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.

Sio Gene Therapies Inc.

Report date April 15, 2019 · Filed April 18, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2029-04-14	Direct	255,000	Reported balance After 2019-04-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-04-15 · Grant · Acquired 255,000 · Balance 255,000 F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of this option will vest on April 15, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARIAD PHARMACEUTICALS INC

Report date February 16, 2017 · Filed February 16, 2017

Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-02-16 transaction · row 1 1 source row Row 1 · 2017-02-16 · Disposition to issuer · Disposed 18,008 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.65	Direct	Reported balance After 2017-02-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-02-16 · Disposition to issuer · Disposed 75,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82	Direct	Reported balance After 2017-02-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.

F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.

F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 01, 2017 Filed Apr 4, 2017 22:05 UTC	CareDx, Inc. CDNA · Entity 4344	GrantCommon Stock	2,243	$0.00	$0.00	Disclosure SEC source: 0000899243-17-009330 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,921 F1 · shares: Represents an automatic, quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document
March 21, 2017 Filed Mar 23, 2017 20:16 UTC	INOVIO PHARMACEUTICALS, INC. INO · Entity 6589	GrantRestricted Stock Unit · Derivative	12,270	$0.00	$0.00	Disclosure SEC source: 0001055726-17-000016 · wf-form4_149030019446771.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,270 Underlying: Common Stock · 12,270 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares will vest on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares will vest on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares will vest on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document
March 21, 2017 Filed Mar 23, 2017 20:16 UTC	INOVIO PHARMACEUTICALS, INC. INO · Entity 6589	GrantCommon Stock Option · Derivative	20,000	$5.86 Strike: $5.86	$117,200.00	Disclosure SEC source: 0001055726-17-000016 · wf-form4_149030019446771.xml · derivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-21 F1 · derivative.exercise_date: The vesting schedule for the 20,000 options is as follows: 5,000 shares vested on March 21, 2017; 5,000 shares will vest on March 21, 2018; 5,000 shares will vest on March 21, 2019; 5,000 shares will vest on March 21, 2020. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:17 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $23.82	$0.00	Disclosure SEC source: 0000884731-17-000057 · wf-form4_148727263228878.xml · derivative · entry 3 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:17 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $6.65	$0.00	Disclosure SEC source: 0000884731-17-000057 · wf-form4_148727263228878.xml · derivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:17 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerCommon Stock	18,008	Not disclosed	Not disclosed	Disclosure SEC source: 0000884731-17-000057 · wf-form4_148727263228878.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2 · price: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document
January 31, 2017 Filed Feb 1, 2017 16:56 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	GrantEmployee Stock Option (Right to Buy) · Derivative	25,000	$23.82 Strike: $23.82	$595,500.00	Disclosure SEC source: 0000884731-17-000014 · wf-form4_148598619527825.xml · derivative · entry 3 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-31 F3 · derivative.exercise_date: The stock options granted under our 2014 Long-Term Incentive Plan, as amended, and in accordance with our director compensation policy vest as to approximately one-fourth of the shares underlying the options on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document
January 31, 2017 Filed Feb 1, 2017 16:56 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	GrantCommon Stock	12,500	$0.00	$0.00	Disclosure SEC source: 0000884731-17-000014 · wf-form4_148598619527825.xml · nonDerivative · entry 2 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,008 F2 · shares: Represents restricted stock units ("RSUs") granted under our 2014 Long-Term Incentive Plan, as amended, and our director compensation policy. The RSUs vest as to approximately one-fourth of the shares underlying the RSUs on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document
January 31, 2017 Filed Feb 1, 2017 16:56 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	GrantCommon Stock	5,508	$0.00	$0.00	Disclosure SEC source: 0000884731-17-000014 · wf-form4_148598619527825.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,508 F1 · shares: Represents shares of restricted stock granted in lieu of the annual cash retainer under our 2014 Long-Term Incentive Plan, as amended, and in accordance with our director compensation policy. The shares are subject to a lapsing right of repurchase by the Company that lapses as to approximately one-fourth of the shares on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document
January 01, 2017 Filed Jan 5, 2017 00:42 UTC	CareDx, Inc. CDNA · Entity 4344	GrantCommon Stock	1,443	$0.00	$0.00	Disclosure SEC source: 0000899243-17-000337 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,678 F1 · shares: Represents an automatic, quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document
October 01, 2016 Filed Oct 4, 2016 23:42 UTC	CareDx, Inc. CDNA · Entity 4344	GrantCommon Stock	1,089	$0.00	$0.00	Disclosure SEC source: 0000899243-16-031002 · doc4.xml · nonDerivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,235 F1 · shares: Represents an automatic, quarterly grant of common stock to the reporting person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy. Read SEC document
June 17, 2015 Filed Jul 15, 2019 20:20 UTC Amendment	CareDx, Inc. CDNA · Entity 4344	GrantStock Option (right to buy) · Derivative	5,255	$0.00 Strike: $5.85	$0.00	Disclosure SEC source: 0000899243-19-019610 · doc4a.xml · derivative · entry 1 Bickerstaff George · CIK 0001329646 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,255 Underlying: Common Stock · 5,255 shares Expires 2025-06-17 F1 · derivative.exercise_price: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. F1 · date: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. F1 · price: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. F1 · derivative.exercise_date: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 17, 2015 and 1/12th of the shares subject to the option shall vest monthly thereafter. F1 · derivative.expiration_date: This amendment is being filed to correct the transaction date, exercise price, date exercisable, expiration date and price of derivative security of the Stock Option (right to buy) reported on the original Form 4. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.